Crossmark

TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis

Crossref DOI link: https://doi.org/10.1007/s12072-023-10591-0

Published Online: 2023-10-16

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Jiaxi

Wang, Peng

Shang, Liqi

Zhang, Zhoubo

Tian, Yulong

Chen, Xiaowei

Ma, Yanan

Shao, Haibo
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No.82072037, 82111530100)

Liaoning Medical-Engineering Cross Fund (2022-YGJC-53)

National Hi-Technology Research and Development Program (No.2012AA022701)

Liaoning BaiQianWan Talents Program
License Information

Text and Data Mining valid from 2023-10-16

Version of Record valid from 2023-10-16
More Information

Article History

Received: 14 May 2023

Accepted: 29 August 2023

First Online: 16 October 2023

Declarations

:

: Jiaxi Liu, Peng Wang, Liqi Shang, Zhoubo Zhang, Yulong Tian, Xiaowei Chen, Yanan Ma, and Haibo Shao declare that they have no conflict of interest.

: Not applicable.

: The informed consent is not applicable because this study is a meta-analysis of published data.

Document is current

Any future updates will be listed below